Hims & Hers Faces FTC Lawsuit and Class Action Over Privacy Practices
Oct 30, 2026, 1:25 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Formal lawsuits and FTC actions introduce incremental downside risk via potential penalties, heightened regulatory scrutiny, and litigation costs. The near-term catalyst is the Nov 2 lead-plaintiff deadline; settlements or adverse rulings could drive further price moves, while absence of material updates may limit upside.
AI summary
What happened, with direct paths to the underlying reporting
Regulators and a plaintiffs' firm filed a federal complaint and class action against Hims & Hers Health, alleging deceptive privacy and billing practices tied to data sharing with advertisers. The class period runs Aug 4, 2025–Jul 29, 2026, and lead-plaintiff motions are due Nov 2, 2026. The news pressured shares and highlights potential penalties and ongoing regulatory risk for HIMS.
FTC sues Hims & Hers for alleged privacy violations; case filed Sept 1, 2026.
Class action covers Aug 4, 2025–Jul 29, 2026; lead plaintiff deadline Nov 2, 2026.
Hims shares fell 14.73% to $25 on July 29, 2026 after FTC news.
FTC complaint cites data-sharing with Meta and Snap and deceptive billing practices.
Lead plaintiff motions due by Nov 2, 2026; no class certified yet.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Kaplan Fox & Kilsheimer LLP filed a class-action against Hims & Hers Health for alleged misstatements during the period from August 4, 2025 to July 29, 2026. The suit highlights p…
Kaplan Fox filed a securities class action against Hims & Hers Health under NYSE: HIMS, covering August 4, 2025 through July 29, 2026. The suit could imply potential securities-la…
The FDA warned about severe health risks from unapproved compounded GLP-1 meds like semaglutide and tirzepatide, citing hundreds of adverse-event reports. Hims & Hers Health share…
Regulators allege Hims & Hers misled patients about prescription timing, privacy, and subscription cancellations, while flagging data sharing with Meta and Snap. The July 29, 2026…